NCT06231407

Brief Summary

The goal of this feasibility and acceptability trial is to learn about the acceptability of adding a recovery-oriented, psychological framework to a standard medication management appointment with a psychiatrist and any impact on attendance and functioning. The main question\[s\] it aims to answer are:

  1. 1.Will CT-R medication checks will be acceptable to the patient and feasible to deliver and receive, as measured by asking patients how they like the CT-R med checks and our ability to do this study in addition to number of patient drop-outs?
  2. 2.Will CT-R medication checks will be related to significantly greater engagement with treatment as measured by: lower no-show rates, greater self-reported working alliance, and better treatment adherence?
  3. 3.Will CT-R medication checks will be related to greater activity and increase in functioning as measured by: time use survey, GAF, skill use?
  4. 4.Will CT-R medication checks will be related to a trend in improved defeatist beliefs, negative symptoms, paranoia, and self-esteem?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 17, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 13, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 19, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 6, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 30, 2024

Completed
Last Updated

January 30, 2024

Status Verified

January 1, 2024

Enrollment Period

1.2 years

First QC Date

July 19, 2023

Last Update Submit

January 27, 2024

Conditions

Keywords

Schizophrenia Spectrum DiagnosisCognitive TherapyCognitive Behavioral Therapy for Psychosis (CBTp)Recovery-Oriented Cognitive Behavioral Therapy for PsychosisCT-RMedication Management Appointments

Outcome Measures

Primary Outcomes (4)

  • Working Alliance Inventory

    Measure of patient perception of working alliance

    Upon Enrollment in the study, Up to 4 months later, At study completion (average of 1 year)

  • Time Use Interview

    Interview capturing amount of time in productive activity.

    Upon Enrollment in the study, Up to 4 months later, At study completion (average of 1 year)

  • Mental Illness Research Education and Clinical Center (MIRECC) Global Assessment of Functioning (GAF)

    Standardized Measure of overall functioning; Scored from 0-100 with higher score indicating better functioning. Scoring is based on predetermined parameters.

    Upon Enrollment in the study, Up to 4 months later, At study completion (average of 1 year)

  • Compass

    Interview of symptoms and their severity.

    Upon Enrollment in the study, Up to 4 months later, At study completion (average of 1 year)

Secondary Outcomes (7)

  • Defeatist Beliefs Scale

    Upon Enrollment in the Study, on average the first of the month until the final assessment (approximately 15 months)

  • Asocial Beliefs Scale

    Upon Enrollment in the Study, on average the first of the month until the final assessment (approximately 15 months)

  • Cognitive Insight Scale

    Upon Enrollment in the Study, on average the first of the month until the final assessment (approximately 15 months)

  • Green Paranoid Thoughts Scale

    Upon Enrollment in the Study, on average the first of the month until the final assessment (approximately 15 months)

  • Self Esteem Scale

    Upon Enrollment in the Study, on average the first of the month until the final assessment (approximately 15 months)

  • +2 more secondary outcomes

Study Arms (2)

Recovery Oriented CBTp Med Check

EXPERIMENTAL

Resident physicians will provide medication appointments, supervised by their attending physician (Stovall) and CT-R supervisor (Brinen). They will conduct their appointment per protocol detailed in a treatment manual. No additional/special information needs to be recorded in medical record, beyond the clinical notes expected per VAPOC policy. Appointments will be a standard length.

Behavioral: Recovery Oriented CBTp Medication Management

Treatment as Usual

ACTIVE COMPARATOR

Patient will attend traditional medication management check appointments with psychiatry residents.

Behavioral: Treatment as Usual

Interventions

The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.

Also known as: Recovery Oriented Cognitive Therapy
Recovery Oriented CBTp Med Check

Residents will conduct medication management appointments as normally conducted

Also known as: TAU
Treatment as Usual

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old
  • Schizophrenia-spectrum disorder
  • Typically scheduled 1x/month
  • Willingness to complete 2-3 hours of testing at multiple timepoints
  • Likely to stay in our clinic for the next 1-2 years

You may not qualify if:

  • Significant intellectual disability
  • Autism spectrum disorder
  • Cannot read/write English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

Location

Related Publications (1)

  • Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry. 2012 Feb;69(2):121-7. doi: 10.1001/archgenpsychiatry.2011.129. Epub 2011 Oct 3.

    PMID: 21969420BACKGROUND

MeSH Terms

Conditions

Schizophrenia

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Subjects were recruited from an existing psychosis clinic and assigned to the participating psychiatry resident. A small group were misaligned and reconnected to use their data as a comparison for someone not receiving the intervention.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Psychiatry and Behavioral Sciences

Study Record Dates

First Submitted

July 19, 2023

First Posted

January 30, 2024

Study Start

March 17, 2022

Primary Completion

June 13, 2023

Study Completion

December 6, 2023

Last Updated

January 30, 2024

Record last verified: 2024-01

Locations